The 5-HT1A receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). It is a G protein-coupled receptor (GPCR) that is coupled to Gi/Go and mediates inhibitory neurotransmission. HTR1A denotes the human gene encoding for the receptor.
The 5-HT1A receptor is the most widespread of all the 5-HT receptors. In the central nervous system, 5-HT1A receptors exist in the cerebral cortex, hippocampus, septum, amygdala, and raphe nucelus in high densities, while low amounts also exist in the basal ganglia and thalamus. The 5-HT1A receptors in the raphe nucleus are largely somatodendritic autoreceptors.
5-HT1A receptor agonists decrease blood pressure and heart rate or cause hypotension via a central mechanism, by inducing peripheral vasodilation, and by stimulating the vagus nerve. These effects are the result of activation of 5-HT1A receptors within the rostral ventrolateral medulla. The sympatholytic antihypertensive drug urapidil is an α1-adrenergic receptor antagonist and α2-adrenergic receptor agonist, as well as 5-HT1A receptor agonist, and it has been demonstrated that the latter property contributes to its overall therapeutic effects.
Vasodilation of the blood vessels in the skin via central 5-HT1A activation increases heat dissipation from the organism out into the environment, causing a decrease in body temperature or hypothermia.
Activation of central 5-HT1A receptors triggers the release or inhibition of norepinephrine depending on species, presumably from the locus coeruleus, which then reduces or increases neuronal tone to the iris sphincter muscle by modulation of postsynaptic α2-adrenergic receptors within the Edinger-Westphal nucleus, resulting in pupil dilation or mydriasis in rodents, and pupil constriction or miosis in primates like humans.
5-HT1A receptor agonists like buspirone and flesinoxan show efficacy in relieving anxiety and depression, and buspirone and tandospirone are currently approved for these indications in various parts of the world. Others such as gepirone, flesinoxan, flibanserin, and PRX-00023 have also been investigated, though none have been fully developed and approved as of yet. Some of the atypical antipsychotics like aripiprazole are also partial agonists at the 5-HT1A receptor and are often used in low doses as augmentations to standard antidepressants like the selective serotonin reuptake inhibitors (SSRIs).
5-HT1A autoreceptor desensitization and increased 5-HT1A receptor postsynaptic activation via general increases in serotonin levels by serotonin precursor supplementation, serotonin reuptake inhibition, or monoamine oxidase inhibition has been shown to be a major mediator in the therapeutic benefits of most mainstream antidepressant supplements and pharmaceuticals, including serotonin precursors like L-tryptophan and 5-HTP, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), and monoamine oxidase inhibitors (MAOIs). 5-HT1A receptor activation likely plays a significant role in the positive effects of serotonin releasing agents (SRAs) like MDMA ("Ecstasy") as well.
5-HT1A receptors in the dorsal raphe nucleus are co-localized with neurokinin 1 (NK1) receptors and have been shown to inhibit the release of substance P, their endogenous ligand. In addition to being antidepressant and anxiolytic in effect, 5-HT1A receptor activation has also been demonstrated to be antiemetic and analgesic, and all of these properties may be mediated in part or full, depending on the property in question, by NK1 receptor inhibition. Consequently, novel NK1 receptor antagonists are now in use for the treatment of nausea and emesis, and are also being investigated for the treatment of anxiety and depression.
5-HT1A receptor activation has been shown to increase dopamine release in the medial prefrontal cortex, striatum, and hippocampus, and may be useful for improving the symptoms of schizophrenia and Parkinson's disease. As mentioned above, some of the atypical antipsychotics are 5-HT1A receptor partial agonists, and this property has been shown to enhance their clinical efficacy. Enhancement of dopamine release in these areas may also play a major role in the antidepressant and anxiolytic effects seen upon postsynaptic activation of the 5-HT1A receptor.
Activation of 5-HT1A receptors has been demonstrated to impair cognition, learning, and memory by inhibiting the release of glutamate and acetylcholine in various areas of the brain. Conversely, 5-HT1A receptor antagonists such as lecozotan have been shown to facilitate certain types of learning and memory in rodents, and as a result, are being developed as novel treatments for Alzheimer's disease.
Other effects of 5-HT1A activation include decreased aggression or increased serenic behavior, increased sociability, increased impulsivity, inhibition of addictive behavior, facilitation of sexual behavior and arousal, inhibition of penile erection, decreased food intake or anorexia, prolongation of REM sleep latency, and enhanced breathing or hyperventilation and reversal of opioid-induced respiratory depression.
5-HT1A receptor activation induces the secretion of various hormones including cortisol, corticosterone, adrenocorticotropic hormone (ACTH), oxytocin, prolactin, growth hormone, and β-endorphin. The receptor does not affect vasopressin or renin secretion, unlike the 5-HT2 receptors. It has been suggested that oxytocin release may contribute to the prosocial, antiaggressive or serenic, and anxiolytic properties observed upon activation of the receptor. β-Endorphin secretion likely contributes to antidepressant, anxiolytic, and analgesic effects.
5-HT1A receptors can be located on the cell body or soma, dendrites, axons, and both presynaptically and postsynaptically in nerve terminals or synapses. Those located on the soma and dendrites are called somatodendritic, and those located presynaptically in the synapse are aptly titled presynaptic. As a group, they are known as autoreceptors. Stimulation of 5-HT1A autoreceptors inhibits the release of serotonin in nerve terminals. For this reason, 5-HT1A receptor agonists tend to exert a biphasic mode of action; they decrease serotonin release and postsynaptic 5-HT1A receptor activity in low doses, and further decrease serotonin release but increase postsynaptic 5-HT1A receptor activity at moderate to high doses by directly stimulating the receptors in replacement of serotonin.
This autoreceptor-mediated inhibition of serotonin release has been postulated to be one of the reasons for the therapeutic lag that is commonly reported for most mainstream serotonergic antidepressants such as the SSRIs. The autoreceptors must first densensitize before the concentration of extracellular serotonin in the synapse can become elevated appreciably. Though the responsiveness of the autoreceptors is somewhat reduced with chronic treatment, they still remain effective at constraining large increases in extracellular serotonin concentrations. For this reason, serotonin reuptake inhibitors that also have 5-HT1A receptor antagonistic properties such as SB-649915 are currently being investigated as novel antidepressants with a faster onset of action and greater efficacy than many of those currently available.
Unlike most drugs that elevate extracellular serotonin levels like the SSRIs and MAOIs, SRAs such as fenfluramine and MDMA ("Ecstasy") fully bypass serotonin autoreceptors like 5-HT1A by forcing release to occur regardless of their inhibition. This is why SRAs display immediate and full effects in contrast to drugs like the SSRIs, which require several weeks of chronic dosing before therapeutic benefits are seen, and also why SRAs are much stronger than SSRIs and related compounds in effect as they produce far more robust and balanced increases in extracellular serotonin concentrations. For these reasons, selective serotonin releasing agents (SSRAs) including MDAI, MMAI, and 4-MTA have been proposed as novel antidepressants with an immediate onset of action and far greater efficacy in comparison to most current treatments.
Sufficient doses of 5-HT1A receptor agonists themselves, like SRAs, are capable of fully bypassing the 5-HT1A autoreceptor-mediated inhibition of serotonin release and therefore decreased 5-HT1A postsynaptic receptor activation as well, by directly agonizing the postsynaptic receptors in lieu of serotonin. It is mentionable, however, that, unlike SRAs, 5-HT1A receptor agonists are incapable of bypassing the inhibitory effect of 5-HT1A autoreceptors located as heteroreceptors in non-serotonergic synapses where 5-HT1A postsynaptic receptors are not present, which, instead of serotonin, modulate the release of other neurotransmitters such as dopamine or glutamate.
The distribution of 5-HT1A receptors in the human brain may be imaged with the positron emission tomography using the radioligand [11C]WAY-100,635. For example, one study has found increased 5-HT1A binding in type 2 diabetes. Another PET study found a negative correlation between the amount of 5-HT1A binding in the raphe nuclei, hippocampus and neocortex and a self-reported tendency to have spiritual experiences. Labeled with tritium, WAY-100,635 may also be used in autoradiography.
- Lu AA21004
The 5-HT1A receptor is coded by the HTR1A gene. There are several human polymorphisms associated with this gene. A 2007 review listed 27 single nucleotide polymorphisms (SNP). The most investigated SNPs are C-1019G (rs6295), C-1018G, Ile28Val (rs1799921), Arg219Leu (rs1800044), and Gly22Ser (rs1799920). Some of the other SNPs are Pro16Leu, Gly272Asp, and the synonymous polymorphism G294A (rs6294). These gene variants have been studied in relation to psychiatric disorders with no definitive results.
The 5-HT1A receptor has been shown to interact with brain-derived neurotrophic factor (BDNF), which may play a major role in its regulation of mood and anxiety. It has also been shown to interact with sphingosine-1-phosphate receptor 1 (S1PR1).
See also Edit
- ↑ Gilliam TC, Freimer NB, Kaufmann CA, Powchik PP, Bassett AS, Bengtsson U, Wasmuth JJ (November 1989). Deletion mapping of DNA markers to a region of chromosome 5 that cosegregates with schizophrenia. Genomics 5 (4): 940–4.
- ↑ Entrez Gene: HTR1A 5-hydroxytryptamine (serotonin) receptor 1A.
- ↑ Ito H, Halldin C, Farde L. (1999). Localization of 5-HT1A receptors in the living human brain using [carbonyl-11C]WAY-100635: PET with anatomic standardization technique.. J Nucl Med. 40 (1): 102–109.
- ↑ 4.0 4.1 Glennon RA, Dukat M, Westkaemper RB. Serotonin Receptor Subtypes and Ligands. American College of Neurophyscopharmacology. URL accessed on 2008-04-11.
- ↑ de Almeida J, Mengod G. (2008). Serotonin 1A receptors in human and monkey prefrontal cortex are mainly expressed in pyramidal neurons and in a GABAergic interneuron subpopulation: implications for schizophrenia and its treatment.. J Neurochem. 107 (2): 488–496.
- ↑ 6.0 6.1 Dabiré H. (1991). Central 5-hydroxytryptamine (5-HT) receptors in blood pressure regulation.. Therapie. 46 (6): 421–9.
- ↑ Ramage AG (April 1991). The mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptors. Br. J. Pharmacol. 102 (4): 998–1002.
- ↑ Kolassa N, Beller KD, Sanders KH. (1989). Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil.. Am J Cardiol. 64 (7): 7D–10D.
- ↑ Ootsuka Y, Blessing WW. (2006). Activation of 5-HT1A receptors in rostral medullary raphé inhibits cutaneous vasoconstriction elicited by cold exposure in rabbits.. Brain Res. 1073-1074: 252–61.
- ↑ Rusyniak DE, Zaretskaia MV, Zaretsky DV, DiMicco JA. (2007). 3,4-Methylenedioxymethamphetamine- and 8-hydroxy-2-di-n-propylamino-tetralin-induced hypothermia: role and location of 5-hydroxytryptamine 1A receptors.. J Pharmacol Exp Ther. 323 (2): 477–487.
- ↑ Yu Y, Ramage AG, Koss MC. (2004). Pharmacological studies of 8-OH-DPAT-induced pupillary dilation in anesthetized rats.. Eur J Pharmacol. 489 (3): 207–213.
- ↑ Prow MR, Martin KF, Heal DJ (1996). 8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation. Eur J Pharmacol. 317 (1): 21–8.
- ↑ Fanciullacci M, Sicuteri R, Alessandri M, Geppetti P (March 1995). Buspirone, but not sumatriptan, induces miosis in humans: relevance for a serotoninergic pupil control. Clinical Pharmacology and Therapeutics 57 (3): 349–55.
- ↑ Cohn, JB, Rickels K (1989). A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Curr Med Res Opin. 11 (5): 304–320.
- ↑ 15.0 15.1 Cryan JF, Redmond AM, Kelly JP, Leonard BE. (1997). The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat.. Eur Neuropsychopharmacol. 7 (2): 109–114.
- ↑ Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (1998). Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci U S A. 195 (18): 10734–9.
- ↑ Kennett GA, Dourish CT, Curzon G (1987). Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol. 134 (3): 265–74.
- ↑ Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J (February 2005). Relapse prevention with gepirone ER in outpatients with major depression. Journal of Clinical Psychopharmacology 25 (1): 79–84.
- ↑ Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R (August 2003). Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors.. Br J Pharmacol. 139 (7): 1281–8.
- ↑ de Paulis T. (2007). Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.. Curr Opin Investig Drugs. 8 (1): 78–86.
- ↑ Stark, AD et al. (2007). Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies.. Psychopharmacology (Berl) 190 (3): 373–382.
- ↑ Vega, JAW, Mortimer AM, Tyson PJ (May 2003). Conventional Antipsychotic Prescription in Unipolar Depression, I: An Audit and Recommendations for Practice. The Journal of Clinical Psychiatry 64 (5): 568–574.
- ↑ Blier P, Abbott FV (January 2001). Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. Journal of Psychiatry & Neuroscience : JPN 26 (1): 37–43.
- ↑ Morley KC, Arnold JC, McGregor IS (June 2005). Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Progress in Neuro-psychopharmacology & Biological Psychiatry 29 (5): 648–57.
- ↑ 25.0 25.1 25.2 Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (May 2007). A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience 146 (2): 509–14.
- ↑ Gobbi G, Cassano T, Radja F, Morgese MG, Cuomo V, Santarelli L, Hen R, Blier P (April 2007). Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 17 (5): 328–38.
- ↑ Baker KG, Halliday GM, Hornung J-P, Geffen LB, Cotton RGH, Tork I. Distribution, morphology and number of monoamine-synthesizing and substance P-containing neurons in the human dorsal raphe nucleus. Neuroscience. 1991;42(3):757-75.
- ↑ Lucot JB (February 1994). Antiemetic effects of flesinoxan in cats: comparisons with 8-hydroxy-2-(di-n-propylamino)tetralin. European Journal of Pharmacology 253 (1-2): 53–60.
- ↑ Oshima T, Kasuya Y, Okumura Y, Terazawa E, Dohi S (November 2002). Prevention of nausea and vomiting with tandospirone in adults after tympanoplasty. Anesthesia and Analgesia 95 (5): 1442–5, table of contents.
- ↑ Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC (April 2003). Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain. Pharmacology 67 (4): 182–94.
- ↑ Colpaert FC (January 2006). 5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Current Opinion in Investigational Drugs (London, England : 2000) 7 (1): 40–7.
- ↑ Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R. (2004). Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response.. J Psychiatry Neurosci. 29 (3): 208–218.
- ↑ 33.0 33.1 Li Z, Ichikawa J, Dai J, Meltzer HY. (2004). Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.. Eur J Pharmacol. 498 (1-3): 75–83.
- ↑ Bantick RA, De Vries MH, Grasby PM. (2005). The effect of a 5-HT1A receptor agonist on striatal dopamine release.. Synapse. 57 (2): 67–75.
- ↑ Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. (2000). 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.. Biol Psychiatry. 48 (3): 229–237.
- ↑ Rollema H, Lu Y, Schmidt AW, Zorn SH. (1997). Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation.. Eur J Pharmacol. 338 (2): R3–5.
- ↑ Yoshino T, Nisijima K, Katoh S, Yui K, Nakamura M (April 2002). Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochemistry International 40 (4): 355–60.
- ↑ Chojnacka-Wójcik E, Tatarczyńska E, Gołembiowska K, Przegaliński E (July 1991). Involvement of 5-HT1A receptors in the antidepressant-like activity of gepirone in the forced swimming test in rats. Neuropharmacology 30 (7): 711–7.
- ↑ Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekström JC, Svenningsson P, Meister B, Kehr J, Stiedl O (2008). The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res. 195 (1): 54–77.
- ↑ H. Spreitzer (August 13, 2008). Neue Wirkstoffe - Lecozotan. Österreichische Apothekerzeitung (17/2007): 805.
- ↑ de Boer SF, Koolhaas JM (2005). 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol. 526 (1-3): 125–39.
- ↑ Olivier B, Mos J, Rasmussen D. (1990). Behavioural pharmacology of the serenic, eltoprazine. Drug Metabol Drug Interact. 8 (1-2): 31–83.
- ↑ Winstanley CA, Theobald DE, Dalley JW, Robbins TW. (2005). Interactions between serotonin and dopamine in the control of impulsive choice in rats: therapeutic implications for impulse control disorders.. Neuropsychopharmacology. 30 (4): 669–682.
- ↑ Tomkins DM, Higgins GA, Sellers EM (1994). Low doses of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH DPAT) increase ethanol intake. Psychopharmacology (Berl). 115 (1-2): 173–9.
- ↑ Müller CP, Carey RJ, Huston JP, De Souza Silva MA (2007). Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors. Prog Neurobiol. 81 (3): 133–78.
- ↑ Carey RJ, DePalma G, Damianopoulos E, Shanahan A, Müller CP, Huston JP (2005). Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects. Brain Res. 1034 (1-2): 162–71.
- ↑ Fernández-Guasti A, Rodríguez-Manzo G (January 1997). 8-OH-DPAT and male rat sexual behavior: partial blockade by noradrenergic lesion and sexual exhaustion. Pharmacology, Biochemistry, and Behavior 56 (1): 111–6.
- ↑ Haensel SM, Slob AK (July 1997). Flesinoxan: a prosexual drug for male rats. European Journal of Pharmacology 330 (1): 1–9.
- ↑ Simon P, Guardiola B, Bizot-Espiard J, Schiavi P, Costentin J (1992). 5-HT1A receptor agonists prevent in rats the yawning and penile erections induced by direct dopamine agonists. Psychopharmacology 108 (1-2): 47–50.
- ↑ Millan MJ, Perrin-Monneyron S (1997). Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors. Eur J Pharmacol. 321 (3): 11–3.
- ↑ Ebenezer IS, Arkle MJ, Tite RM (1998). 8-Hydroxy-2-(di-n-propylamino)-tetralin inhibits food intake in fasted rats by an action at 5-HT1A receptors. Methods Find Exp Clin Pharmacol. 29 (4): 269–72.
- ↑ Monti JM, Jantos H (1992). Dose-dependent effects of the 5-HT1A receptor agonist 8-OH-DPAT on sleep and wakefulness in the rat. J Sleep Res. 1 (3): 169–175.
- ↑ Marc Ansseau, William Pitchot, Antonio Gonzalez Moreno, Jacques Wauthy, Patrick Papart (2004). Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature.. Human Psychopharmacology: Clinical and Experimental 8 (4): 279–283.
- ↑ Meyer LC, Fuller A, Mitchell D (February 2006). Zacopride and 8-OH-DPAT reverse opioid-induced respiratory depression and hypoxia but not catatonic immobilization in goats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 290 (2): R405–13.
- ↑ 55.0 55.1 Van de Kar LD, Levy AD, Li Q, Brownfield MS. (1998). A comparison of the oxytocin and vasopressin responses to the 5-HT1A agonist and potential anxiolytic drug alnespirone (S-20499).. Pharmacol Biochem Behav. 60 (3): 677–683.
- ↑ 56.0 56.1 Lorens SA, Van de Kar LD. (1987). Differential effects of serotonin (5-HT1A and 5-HT2) agonists and antagonists on renin and corticosterone secretion.. Neuroendocrinology. 45 (4): 305–310.
- ↑ Koenig JI, Gudelsky GA, Meltzer HY. (1987). Stimulation of corticosterone and beta-endorphin secretion in the rat by selective 5-HT receptor subtype activation.. Eur J Pharmacol. 137 (1): 1–8.
- ↑ Pitchot W, Wauthy J, Legros JJ, Ansseau M (March 2004). Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 14 (2): 151–5.
- ↑ 59.0 59.1 59.2 Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB. (2000). Serotonin autoreceptor function and antidepressant drug action.. J Psychopharmacol. 14 (2): 177–185.
- ↑ Briley M, Moret C. (1993). Neurobiological mechanisms involved in antidepressant therapies.. Clin Neuropharmacol. 16 (5): 387–400.
- ↑ Starr KR, Price GW, Watson JM, Atkinson PJ, Arban R, Melotto S, Dawson LA, Hagan JJ, Upton N, Duxon MS. (2007). SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test.. Neuropsychopharmacology. 32 (10): 2163–2172.
- ↑ Rothman RB, Baumann MH (2006). Therapeutic potential of monoamine transporter substrates. Current Topics in Medicinal Chemistry 6 (17): 1845–59.
- ↑ 63.0 63.1 Scorza C, Silveira R, Nichols DE, Reyes-Parada M (July 1999). Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action. Neuropharmacology 38 (7): 1055–61.
- ↑ Marona-Lewicka D, Nichols DE (July 1998). Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology 138 (1): 67–75.
- ↑ Pike VW, McCarron JA, Lammerstma AA, Hume SP, Poole K, Grasby PM, Malizia A, Cliffe IA, Fletcher A, Bench CJ (1995). First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. Eur. J. Pharmacol. 283 (1-3): R1–3.
- ↑ Price JC, Kelley DE, Ryan CM, Meltzer CC, Drevets WC, Mathis CA, Mazumdar S, Reynolds CF (2002). Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study. Brain Res. 927 (1): 97–103.
- ↑ Borg J, Andrée B, Soderstrom H, Farde L (November 2003). The serotonin system and spiritual experiences. Am J Psychiatry 160 (11): 1965–9.
- ↑ Burnet PW, Eastwood SL, Harrison PJ (1997). [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Int. 30 (6): 565–574.
- ↑ 69.0 69.1 69.2 Drago A, Ronchi DD, Serretti A (August 2008). 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int. J. Neuropsychopharmacol. 11 (5): 701–21.
- ↑ Wu S, Comings DE (June 1999). A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr. Genet. 9 (2): 105–6.
- ↑ Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E et al. (2007). Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression.. J Neural Transm 114 (8): 1065–8.
- ↑ Guiard BP, David DJ, Deltheil T, Chenu F, Le Maître E, Renoir T et al. (2008). Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype.. Int J Neuropsychopharmacol 11 (1): 79–92.
- ↑ Salim, Kamran, Fenton Tim, Bacha Jamil, Urien-Rodriguez Hector, Bonnert Tim, Skynner Heather A, Watts Emma, Kerby Julie, Heald Anne, Beer Margaret, McAllister George, Guest Paul C (May. 2002). Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation. J. Biol. Chem. 277 (18): 15482–5.
Further reading Edit
- el Mestikawy S, Fargin A, Raymond JR, et al. (1991). The 5-HT1A receptor: an overview of recent advances. Neurochem. Res. 16 (1): 1–10.
- Hensler JG (2003). Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci. 72 (15): 1665–82.
- Van Oekelen D, Luyten WH, Leysen JE (2003). 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci. 72 (22): 2429–49.
- Lesch KP, Gutknecht L (2005). Focus on The 5-HT1A receptor: emerging role of a gene regulatory variant in psychopathology and pharmacogenetics. Int. J. Neuropsychopharmacol. 7 (4): 381–5.
- Kalipatnapu S, Chattopadhyay A (2006). Membrane protein solubilization: recent advances and challenges in solubilization of serotonin1A receptors. IUBMB Life 57 (7): 505–12.
- Varrault A, Bockaert J, Waeber C (1992). Activation of 5-HT1A receptors expressed in NIH-3T3 cells induces focus formation and potentiates EGF effect on DNA synthesis. Mol. Biol. Cell 3 (9): 961–9.
- Levy FO, Gudermann T, Perez-Reyes E, et al. (1992). Molecular cloning of a human serotonin receptor (S12) with a pharmacological profile resembling that of the 5-HT1D subtype. J. Biol. Chem. 267 (11): 7553–62.
- Melmer G, Sherrington R, Mankoo B, et al. (1992). A cosmid clone for the 5HT1A receptor (HTR1A) reveals a TaqI RFLP that shows tight linkage to dna loci D5S6, D5S39, and D5S76. Genomics 11 (3): 767–9.
- Parks CL, Chang LS, Shenk T (1992). A polymerase chain reaction mediated by a single primer: cloning of genomic sequences adjacent to a serotonin receptor protein coding region. Nucleic Acids Res. 19 (25): 7155–60.
- Gilliam TC, Freimer NB, Kaufmann CA, et al. (1990). Deletion mapping of DNA markers to a region of chromosome 5 that cosegregates with schizophrenia. Genomics 5 (4): 940–4.
- Kobilka BK, Frielle T, Collins S, et al. (1987). An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature 329 (6134): 75–9.
- Fargin A, Raymond JR, Lohse MJ, et al. (1988). The genomic clone G-21, which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 335 (6188): 358–60.
- Nakhai B, Nielsen DA, Linnoila M, Goldman D (1995). Two naturally occurring amino acid substitutions in the human 5-HT1A receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28. Biochem. Biophys. Res. Commun. 210 (2): 530–6.
- Aune TM, McGrath KM, Sarr T, et al. (1993). Expression of 5HT1a receptors on activated human T cells. Regulation of cyclic AMP levels and T cell proliferation by 5-hydroxytryptamine. J. Immunol. 151 (3): 1175–83.
- Parks CL, Shenk T (1996). The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1. J. Biol. Chem. 271 (8): 4417–30.
- Stockmeier CA, Shapiro LA, Dilley GE, et al. (1998). Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J. Neurosci. 18 (18): 7394–401.
- Kawanishi Y, Harada S, Tachikawa H, et al. (1998). Novel mutations in the promoter and coding region of the human 5-HT1A receptor gene and association analysis in schizophrenia. Am. J. Med. Genet. 81 (5): 434–9.
- Salim K, Fenton T, Bacha J, et al. (2002). Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation. J. Biol. Chem. 277 (18): 15482–5.
- 5-HT1A. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
Cell physiology: cell signaling
|Types of proteins|